This article covers 5 clinical trials in various stages.

     The GM-CSF (granulocyte-macrophage colony-stimulating factor) Tumor Cell vaccine is part of the GVAX suite of vaccines from Cell GeneSys. The vaccine works through the injection of irradiated, non-growing prostate cancer cells that secrete GM-CSF. The GM-CSF acts to recruit the immune cells (specifically dendritic cells) to the site of the vaccine and produce an immune response. The immune response then acts to target any prostate cancer cell within the body. This vaccine is in clinical phase III trials and currently recruiting. The phase II trials, the time to disease progression in metastaticterm bone disease was almost doubled in treated patients.